BroadOak Partners advises Nanosyn on the sale of the company to Element Materials Technology ("Element"). Nanoysn is a full-service drug discovery CDMO that provides chemistry, biology, API, and formulation services to pharmaceutical companies.
Element further bolsters its pharmaceuticals offering with Nanosyn acquisition
London, UK – October 11, 2021 – Element Materials Technology (Element) has acquired Nanosyn, a full-service pharmaceuticals contract development and manufacturing organization, significantly strengthening Element's offering for pharmaceutical and biopharmaceutical customers in North America.
Nanosyn is a leader in drug discovery and small-batch manufacturing of active pharmaceutical ingredients. It has a track record of providing the highest quality services and operates three facilities in the San Francisco Bay Area of approximately 100,000 sq.ft, two of which are FDA registered.
With a team of more than 75 scientists and experts, more than half of whom have a PhD in a scientific discipline, Nanosyn will bolster Element's breadth of technical services bringing cutting edge innovation and high growth. The team will support pharmaceuticals and biopharmaceuticals customers from early-stage discovery, through clinical trials, formulation, and regulatory approval.
Jo Wetz, Element CEO, said: "This is our fifth acquisition in the life sciences sector this year."
Nikolai Sepetov PhD, Nanosyn CEO, said: "Nanosyn has a 23 year track record of supporting numerous drug discovery and development programs which have led to over fifty clinical candidates and several marketed drugs."